Agenix cuts COO position
Thursday, 27 October, 2005
Brad Calvin is to step down as chief operating officer of Agenix (ASX:AGX) today after the company decided not to renew his employment contract.
Agenix managing director Donald Home will take on Calvin's responsibilities.
The company said Calvin was initially employed to lead the sales and marketing of the Agenix's Animal Health, Human Health and Milton Pharmaceuticals businesses and to assist in the commercialisation of the company's ThromboView product.
Agenix has since divested Milton Pharmaceuticals and entered into an agreement for the global sales, marketing and distribution of ThromboView and the company decided that its requirements for the Animal and Human Health businesses "did not warrant the current level of staffing".
Does exercise really extend lifespan? It's complicated
Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
